pharmaceutical industry and the supply of highly qualified medicines with the most advanced facilities according to KGMP. These efforts has made Hanmi one of the leading and promising pharmaceutical companies in Korea. So, Hanmi has showed continuous annual growth of 20%~30% since its establishment in 1973. And in 2003, its amount of total sales was nearly 243 billion won.
In 2000, all Korean p
pharmaceutical company
We met the vice president of this company, who also in charging of director of sales department. He shows the typical relationship-oriented leader. We asked him that how he put balance between work and relation, he replied that he tried to focus on task. However he was much interested in making relation with his followers than others. Though he is at the high position, he
1. History and introduction of Dong A pharmaceutical
Dong-A Pharmaceutical is the leading pharmaceutical company in Korea. Dong-A stands at the forefront of Korea's pharmaceutical industry; motivated by its respect for life and health to continuously innovate and develop products that enhance people's quality of life. We are working hard to grow internationally and become one of the world's most
pharmaceutical company concentrated on R&Ds, Merck is performing various researches and developments upon medical supplies for human and animals. Merck is providing Pharmaceutical Benefit Management (i.e. PBM) through a company called Merck-Medco Managed Care. Apparently it is a giant pharmaceutical company with more than 15 blockbuster medical supplies, revenue of $3270 million and net profit of
REBATE?
Literally
Paying back a portion of the payment or interest to the payee
In the field of medicine
Pharmaceutical company pays back to the hospital
through negative market
Cause of Rebate in Korea
K-1. Special characteristics of Medical industry
Patients have no option in choice of drugs
Doctors have the incentive to use their
professionalism to maximize their p
camera, Such as film, photo paper
Kay Whitmore
1983, Overcoming of the crisis found
in ”Industrial diversification”
Start 1988 with the acquisition of pharmaceutical company ”Sterling”
Office equipment and medical equipment to expand a new business
1. Overview
1980s
Recognized the potential of modern biotechnology
Early1990s
Stopped or reduced their research & efforts in biotechnology
Late 1990s
Only food and beverage enterprise, pharmaceutical and chemical companies invested significantly
Takeda Pharmaceutical Enterprise
focused on metabolic disorders, neurology, inflammation,
as well as oncology through its independe
Companies and products
1. Company Overview
- Company Name : Kwang Dong Pharmaceutical CO.
- Corporate Philosophy : Development of creative medicine, Scientific analysis of -traditional Oriental medicine
- Assets Scale : 169100000000 won
- Products : Medicines, Health Drink, Health Food etc.
자료제공: KADD 기간: 2004년 1월-2004년 6
pharmaceutical product is not valuable, inexpensive, easy to get.
Bargaining
Power of buyers
Low Before the prescription regulations buyers can get pills more easily.
But after prescription requirement regulations their option decreased.
Threat of
substitute
Low It can say “ there are no substitute”
Because of high regulations, product which have
companies can not be a contender)
Investment burden of R&D
Great burden on facilities of sap
Greater burden on patent protection for new drugs
Strengthening government regulation of the licensing
Economies of scale in the industry
2. Bargaining power of suppliers
(Low bargaining power of suppliers
in the pharmaceutical industry )
The pr